The Study of Tamoxifen and Raloxifene (STAR) is a clinical trial from the early 2000s designed determine how the drug raloxifene compares with the drug tamoxifen in reducing the incidence of breast cancer in women who are at increased risk of the disease.
Research One of the largest breast cancer prevention studies ever,"Osteoporosis drug equals tamoxifen in preventing breast cancer", Pittsburgh Post-Gazette, April 18, 2006 it included 22,000 women in 400 medical centers in the United States and Canada."Drug Slashes Breast Cancer Risk, Study Shows", New York Times, June 16, 1999
The study concluded that raloxifene caused fewer side-effects and less endometrial cancer than tamoxifen."Raloxifene or tamoxifen: Which is the right drug for you?", USA Today, April 17, 2006 Raloxifene was found to be more effective at preventing noninvasive breast cancer but less effective at preventing invasive breast cancer."Raloxifene, Tamoxifen Both Guard Against Breast Cancer", Business Week, April 19, 2010
References
External links Study of Tamoxifen and Raloxifene (STAR) Trial